• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Hard To Treat Diseases (HTDS) Set To Acquire Cosmetics Company

Posted on: Wednesday, 7 January 2009, 06:30 CST

CLEARWATER, FL, Jan. 7 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com the company is pleased to announce that it has identified a cosmetics company as a potential merger candidate. The cosmetics company also located in E Europe (Serbia) is engaged in online sales of the "Melem" product. Melem is a versatile, all-purpose skin and lip balm. It has a wide variety of skin and lip problems including eczema, psoriasis, chapped skin and lips, calluses, sunburns, insect bites and much more.

Andrea Rubio Zecevic, who currently acts as a head scientific advisor to HTDS said "Just to be clear, the Melem cosmetics company is not the core business of HTDS by any stretch of the imagination. It's a small self supporting cosmetics company and a nice add on for HTDS. The opportunities in this region due to the Balkan wars of the 1990s are enormous. There are various European Union reconstruction programs and enticements in place while the whole country is in the process of privatizing its entire infrastructure. Just to give our readers an example, HTDS will pay for the Melem cosmetics company a sum equivalent to a price of a USA based mid-sized car. This includes all the formulas, packaging the good will, the client base and whole back office. This is a fraction of the reproduction cost had we bought a similar company just 300-400 miles west in Switzerland or Austria or any other western European country. The company will complete the transaction on all cash basis. Currently this region of the world is celebrating the Orthodox Christmas. As soon as these holidays are behind them, we expect the final documents will be executed and the merger company name announced. In addition we are in contact with the Chief Scienist Dr. Sanja Pekovic who will shortly after the holidays commence furnishing us with regular updates on the progress her team has made with their work (see www.slavicabiochem.com for details). Our aspirations for the merger with the Chinese based medical company engaged in the similar research as Slavica continues. The synergies are definitely present. Our representatives will be in Beijing next week and we should have some preliminary news to report on that front as well."

The company will provide further details as they become available.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

CONTACT: For scientific dialogue and any medical inquiry only please contact Andrea Rubio Zecevic via e-mail at azconsulting2001@gmail.com. For any corporate matters the readers should contact the company directly at corporate@htdsmedical.com

CONTACT: For scientific dialogue and any medical inquiry only please contact Andrea Rubio Zecevic via e-mail at azconsulting2001@gmail.com. For any corporate matters the readers should contact the company directly at corporate@htdsmedical.com

SOURCE Hard to Treat Diseases

Source: PR Newswire

More News in this Category